Abstract: Impact Therapeutics, a China-based near-commercial-stage biopharma company, is looking to raise at least USD 100 million via a Hong Kong listing. GS and CICC are the joint sponsors. In our previous note, we looked at the company’s core products, senaparib/IMP4297, and key products IMP1734 and IMP9064. We also looked at the company’s pre-IPO investors and management team. In this note, we look at the latest prospectus and analyze changes in the company's pipeline and competitive landscapes.
JIANGSU HENGRUI PHARMACEUTICALS, HANSOH PHARMACEUTICAL, ZAI LAB
Interested in the full report? Get in touch with our team.